Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.

The Lancet. Oncology·2026
Same author

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

Journal for immunotherapy of cancer·2026
Same author

The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.

BMJ open·2026
Same author

Mitochondria-targeted OXPHOS inhibition enhances radiotherapy efficacy by disrupting mitochondrial function.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Leveraging [<sup>18</sup>F]F-Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer.

Clinical and translational science·2026

Related Experiment Video

Updated: May 2, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer

Frederik R Teunissen1, Daniela E Oprea-Lager2, Steffie M B Peters2

  • 1Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; and freek.teunissen@radboudumc.nl.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|October 3, 2025
PubMed
Summary
This summary is machine-generated.

Combining external-beam radiotherapy (EBRT) with 177Lu-labeled prostate-specific membrane antigen (PSMA) ligands shows promise for improving prostate cancer outcomes. Further research is needed to optimize this combined therapeutic approach.

Keywords:
EBRT[177Lu]Lu-PSMAdosimetryexternal-beam radiotherapyprostate cancerradiopharmaceutical therapy

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.9K

Related Experiment Videos

Last Updated: May 2, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.9K

Area of Science:

  • Oncology
  • Radiotherapy
  • Nuclear Medicine

Background:

  • External-beam radiotherapy (EBRT) is a standard treatment for prostate cancer.
  • 177Lu-labeled prostate-specific membrane antigen (PSMA) ligands offer targeted radionuclide therapy.
  • Combining these modalities may enhance treatment efficacy.

Purpose of the Study:

  • To review preclinical and clinical studies on the combination of EBRT and 177Lu-labeled PSMA ligands.
  • To explore ongoing trials and future research directions for this combined therapy.
  • To assess the potential benefits and challenges of this emerging approach.

Main Methods:

  • Comprehensive literature search of online research and trial databases (PubMed, ClinicalTrials.gov).
  • Inclusion of preclinical studies, clinical reports, and ongoing prospective trials.
  • Analysis of treatment outcomes, patient populations, and therapeutic schedules.

Main Results:

  • Preclinical study showed improved tumor growth delay and survival with combined therapy.
  • Clinical reports indicated tumor regression in metastatic lesions and increased biologically effective dose.
  • Ten ongoing trials are investigating various aspects of combined EBRT and 177Lu-PSMA ligand therapy.

Conclusions:

  • The combination of EBRT and 177Lu-PSMA ligands demonstrates potential for improved prostate cancer tumor control without increased toxicity.
  • Optimal treatment scheduling, dosing, dosimetry, and specific indications require further investigation.
  • Robust preclinical and clinical research is essential to guide future clinical trials and optimize patient outcomes.